Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05419505 · ClinicalTrials.gov registry record · Phase 2
Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks
A Phase 2 study of Cellulite and Edematous Fibrosclerotic Panniculopathy, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
- 13
- Study locations
NCT05419505 is a Phase 2 study of Cellulite and Edematous Fibrosclerotic Panniculopathy that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 91 participants, below the 154-participant average among 5 other Cellulite trials with a reported enrollment target (41% lower). The trial reports 13 study locations across 9 states.
The verdict
NCT05419505, a Phase 2 study of Cellulite and Edematous Fibrosclerotic Panniculopathy, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
- 13
- Study locations
Study Summary
The study will evaluate the effect of different doses, strengths (concentrations), diluent additives, depths of injection, and methods of injection on the severity of bruising potentially induced by QWO (collagenase clostridium histolyticum-aaes \[CCH-aaes\]).
Conditions Studied
Interventions
- DRUG CCH-aaes
- DRUG Antifibrinolytic Agent
Study Locations (13)
California
- Endo Clinical Trial Site #4 - Beverly Hills
- Endo Clinical Trial Site #9 - Encinitas
- Endo Clinical Trial Site #10 - San Diego
- Endo Clinical Trial Site #7 - Solana Beach
Florida
- Endo Clinical Trial Site #8 - Coral Gables
- Endo Clinical Trial Site #13 - Miami
Arizona
- Endo Clinical Trial Site #6 - Scottsdale
Colorado
- Endo Clinical Trial Site #12 - Greenwood Village
Illinois
- Endo Clinical Trial Site #3 - Chicago
Louisiana
- Endo Clinical Trial Site #2 - Metairie
New York
- Endo Clinical Trial Site #11 - New York
Tennessee
- Endo Clinical Trial Site #1 - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2022-06-15 |
| Est. Completion | 2023-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05419505
The ClinicalTrials.gov registry entry for NCT05419505 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 154-participant average among 5 other Cellulite trials with a reported enrollment target (41% lower). The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cellulite appearing as the primary indexed condition, and to 2 interventions - of which CCH-aaes is the first listed.
NCT05419505 reports 13 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05419505 about?
NCT05419505 is a clinical study titled "Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks". The study will evaluate the effect of different doses, strengths (concentrations), diluent additives, depths of injection, and methods of injection on the severity of bruising potentially induced by QWO (collagenase clostridium histolyticum-aaes \[CCH-aaes\]).
What is the current status of trial NCT05419505?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2022-06-15. Estimated completion is 2023-06-21.
What conditions does trial NCT05419505 study?
This clinical trial studies the following conditions: Cellulite, Edematous Fibrosclerotic Panniculopathy.
What interventions are being tested in trial NCT05419505?
The interventions under investigation include: CCH-aaes (DRUG), Antifibrinolytic Agent (DRUG).
Who is sponsoring clinical trial NCT05419505?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05419505 being conducted?
This trial has 13 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cellulite
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)
COMPLETED · Phase 2
-
Minimally Invasive Active Release of Septa Bands for Cellulite and Connective Tissue Release for Fibrosis Treatment in Body Contouring Surgery
RECRUITING · NA
-
Cyrolipolysis vs Cyrolipolysis and Subcision for Cellulite
ACTIVE NOT RECRUITING · NA
-
The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
COMPLETED · Phase 1
-
Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.